Beijing, China

Maengsup Kim


 

Average Co-Inventor Count = 5.1

ph-index = 2

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2016-2025

where 'Filed Patents' based on already Granted Patents

11 patents (USPTO):

Title: Maengsup Kim: Innovator in Bispecific Antibody Development

Introduction

Maengsup Kim is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies. With a total of 11 patents to his name, Kim's work focuses on innovative solutions for complex diseases.

Latest Patents

Among his latest patents is the "Anti-TNFα/anti IL-17A natural antibody structure-like heterodimer form of bispecific antibody and preparation method therefor." This invention provides a bispecific antibody capable of binding two target molecules simultaneously, offering potential treatments for complex diseases. Another notable patent is the "Anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof." This highly stable bispecific antibody maintains natural IgG characteristics and is free of mismatched heavy and light chains, enhancing its efficacy in treating complicated diseases.

Career Highlights

Maengsup Kim is currently employed at Beijing Hanmi Pharmaceutical Co., Ltd. His work at this leading pharmaceutical company has allowed him to focus on groundbreaking research and development in antibody therapies. His innovative approaches have positioned him as a key figure in the biotechnology sector.

Collaborations

Kim collaborates with talented professionals in his field, including Mi Young Cha and Jiawang Liu. These partnerships enhance the research and development process, fostering an environment of innovation and creativity.

Conclusion

Maengsup Kim's contributions to bispecific antibody development are noteworthy and impactful. His innovative patents and collaborations reflect his commitment to advancing medical science and improving treatment options for complex diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…